The company is showcasing newly cleared tests and platforms for multiple myeloma, lung cancer, connective tissue disease, and other laboratory applications.
Thermo Fisher Scientific is presenting its latest diagnostic developments and regulatory milestones at the Association for Diagnostics and Laboratory Medicine (ADLM) conference in Anaheim, California, from July 26-30, 2026. The company’s presence focuses on specialty diagnostics, quality management, and workflow solutions for clinical laboratories.
“Laboratories today face growing pressure to deliver faster, more accurate results while managing operational complexity,” says Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher, in a release. “At the same time, the traditional boundaries between research, translational medicine and diagnostics continue to blur as science advances and healthcare evolves.”
New Clearances for Multiple Myeloma and Oncology
The EXENT Solution, an automated mass spectrometry platform designed to assist in the diagnosis of multiple myeloma and related disorders, recently received 510(k) clearance from the Food and Drug Administration (FDA). According to the International Myeloma Foundation, more than 176,000 people are diagnosed with multiple myeloma annually. The system combines automated workflows with increased sensitivity to help laboratories provide results for clinical decision-making.
In the field of oncology, the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer received FDA approval in 2025. It is used as a companion diagnostic for sunvozertinib in non-small cell lung cancer and for tumor profiling in formalin-fixed paraffin-embedded samples. The integrated system can provide next-generation sequencing results within 24 hours.
Diagnostics for Autoimmune and Maternal Health
The company also highlighted the EliA CTD 13 Screen, which received FDA 510(k) clearance in June 2026. This assay provides laboratories with a new option for systemic connective tissue disease testing. Available on the Phadia 250 instrument, it is intended to aid in the diagnosis of conditions such as systemic lupus erythematosus, Sjogren syndrome, systemic sclerosis, and mixed connective tissue disease when used with other laboratory and clinical findings.
Thermo Fisher is also featuring its B·R·A·H·M·S biomarker portfolio, which includes procalcitonin testing for antibiotic stewardship in sepsis management. The portfolio also contains the PreClara Ratio, an FDA-cleared biomarker test for assessing the risk of preeclampsia.
Quality Management and Research Tools
For quality management, the company is showcasing LabLink360 and MAS Max quality controls. LabLink360 includes Sigma-metric analysis, a benchmarking tool that allows laboratories to evaluate performance and optimize quality control parameters to reduce operational burdens.
In the research and molecular space, the Thermo Scientific TSQ Certis Triple Quadrupole Mass Spectrometer, launched in late 2025, is designed for high sensitivity in workflows such as toxicology and immunosuppressant drug monitoring. Additionally, the Applied Biosystems QuantStudio Dx Real-Time PCR System is on display for infectious disease testing and pathogen detection in public health laboratories.
ID 272215603 © Jetcityimage | Dreamstime.com
